Included in the formulation
АТХ:G.03.G.A Gonadotropins
G.03.G.A.07 Lutropin alfa
Pharmacodynamics:Binding to the receptors of luteinizing hormone. The action is similar to that of a luteinizing hormone, so it is usually used as a substitute for it.
Pharmacokinetics:Bioavailability is 56 ± 23%. Half-life - 11-18 hours Elimination is carried out by the kidneys (less than 5% unchanged).
Indications:Treatment of infertility due to hypothalamic-pituitary disorders, leading to a decrease in the level of luteinizing and follicle-stimulating hormones in the body.
XIV.N80-N98.N97 Female infertility
Contraindications:Hypersensitivity, hypothalamic-pituitary tumors, hyperprolactinaemia, decompensated pathology of the thyroid and adrenal glands, persistent ovarian enlargement, ovarian cyst (not caused by polycystic ovary syndrome), polycystic ovary syndrome, genital abnormalities (incompatible with normal pregnancy), uterine fibroids, uterine bleeding of unclear etiology, estrogen-dependent tumors (ovarian cancer, uterine cancer, breast cancer), primary ovarian failure, birch con- cern, breastfeeding.
Carefully:Diseases of the adrenal cortex, thyroid gland, tumors (intracranial or hormone-dependent); bronchial asthma.
Pregnancy and lactation:The drug is contraindicated in pregnancy and lactation.
The category of recommendations of the FDA is X.
Dosing and Administration:The drug is administered every day for 3 weeks in parallel with injections of follicle-stimulating hormone.
Typically, start with a dose of 75 IU of the drug (1 vial) along with 75 ME or 150 ME follicle-stimulating hormone. Depending on the response of the ovaries, a dose increase follicle-stimulating hormone about 37.5-75 ME every 7-14 days.
In some cases it may be necessary to extend the treatment to 5 weeks.
When the desired result is achieved 24-48 hours after the last injection of the drug and follicle-stimulating hormone a single injection of human chorionic gonadotropin at a dose of 5,000-10,000 IU or 250 μg of recombinant human chorionic gonadotropin. It is recommended to have sexual contact on the day of administration human chorionic gonadotropin and the next day.
Side effects:From the digestive system: often - pain in the abdomen, nausea, vomiting.
From the side of the central nervous system: often - headache, drowsiness.
On the part of the reproductive system: often - pain in the mammary glands, ovarian cysts.
Local reactions: there may be pain, redness, itching, swelling, bruising.
Overdose:Ovarian hyperstimulation syndrome: the formation of large ovarian cysts with their risk of rupture (perforation), the symptoms of ascites and circulatory disorders.
Treatment: withdrawal of the drug, sexual abstinence or use of barrier methods of contraception for 4 days or more.
Interaction:Do not mix the drug with other medicinal substances in one syringe with the exception of foliotropin alfa.
Special instructions:The main indication for use is the treatment of infertility (male and female) and sexual development disorders caused by deficiency of gonadotropic hormones.
Gonadotropic hormones are the most effective means for carrying out intrauterine insemination (in combination with ovarian hyperstimulation). Should be prescribed the lowest dose (50-75 IU per day), as increasing the dose does not increase the chance of pregnancy, but it increases the risk of ovarian hyperstimulation syndrome (43 studies, 3957 participants).
Monitoring (in women): determination of the concentration of estradiol and progesterone, ultrasonography (for assessing the maturation of follicles and early diagnosis of ovarian hyperstimulation syndrome), basal temperature measurement.
Distinctive characteristics
Recombinant human luteinizing hormone is a product of genetic engineering derived from genetically modified Chinese hamster ovary cells.